Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2013

Open Access 01-12-2013 | Research

Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients

Authors: Rajendra Gharbaran, Andre Goy, Takemi Tanaka, Jongwhan Park, Chris Kim, Nafis Hasan, Swathi Vemulapalli, Sreeja Sarojini, Madalina Tuluc, Kip Nalley, Pritish Bhattacharyya, Andrew Pecora, K Stephen Suh

Published in: Journal of Hematology & Oncology | Issue 1/2013

Login to get access

Abstract

Background

High risk, unfavorable classical Hodgkin lymphoma (cHL) includes those patients with primary refractory or early relapse, and progressive disease. To improve the availability of biomarkers for this group of patients, we investigated both tumor biopsies and peripheral blood leukocytes (PBL) of untreated (chemo-naïve, CN) Nodular Sclerosis Classic Hodgkin Lymphoma (NS-cHL) patients for consistent biomarkers that can predict the outcome prior to frontline treatment.

Methods and materials

Bioinformatics data mining was used to generate 151 candidate biomarkers, which were screened against a library of 10 HL cell lines. Expression of FGF2 and SDC1 by CD30+ cells from HL patient samples representing good and poor outcomes were analyzed by qRT-PCR, immunohistochemical (IHC), and immunofluorescence analyses.

Results

To identify predictive HL-specific biomarkers, potential marker genes selected using bioinformatics approaches were screened against HL cell lines and HL patient samples. Fibroblast Growth Factor-2 (FGF2) and Syndecan-1 (SDC1) were overexpressed in all HL cell lines, and the overexpression was HL-specific when compared to 116 non-Hodgkin lymphoma tissues. In the analysis of stratified NS-cHL patient samples, expression of FGF2 and SDC1 were 245 fold and 91 fold higher, respectively, in the poor outcome (PO) group than in the good outcome (GO) group. The PO group exhibited higher expression of the HL marker CD30, the macrophage marker CD68, and metastatic markers TGFβ1 and MMP9 compared to the GO group. This expression signature was confirmed by qualitative immunohistochemical and immunofluorescent data. A Kaplan-Meier analysis indicated that samples in which the CD30+ cells carried an FGF2+/SDC1+ immunophenotype showed shortened survival. Analysis of chemo-naive HL blood samples suggested that in the PO group a subset of CD30+ HL cells had entered the circulation. These cells significantly overexpressed FGF2 and SDC1 compared to the GO group. The PO group showed significant down-regulation of markers for monocytes, T-cells, and B-cells. These expression signatures were eliminated in heavily pretreated patients.

Conclusion

The results suggest that small subsets of circulating CD30+/CD15+ cells expressing FGF2 and SDC1 represent biomarkers that identify NS-cHL patients who will experience a poor outcome (primary refractory and early relapsing).
Appendix
Available only for authorised users
Literature
1.
Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A: Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin lymphoma study group. Blood. 2000, 96 (4): 1280-1286.PubMed
2.
Majhail NS, Ness KK, Burns LJ, Sun CL, Carter A, Francisco L, Forman SJ, Bhatia S, Baker KS: Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study. Biol Blood Marrow Transplant. 2007, 13 (10): 1153-1159. 10.1016/j.bbmt.2007.06.003.PubMedCentralCrossRefPubMed
3.
Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N Engl J Med. 1998, 339 (21): 1506-1514. 10.1056/NEJM199811193392104.CrossRefPubMed
4.
Steidl C, Farinha P, Gascoyne RD: Macrophages predict treatment outcome in Hodgkin’s lymphoma. Haematologica. 2011, 96 (2): 186-189. 10.3324/haematol.2010.033316.PubMedCentralCrossRefPubMed
5.
Azambuja D, Natkunam Y, Biasoli I, Lossos IS, Anderson MW, Morais JC, Spector N: Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin’s lymphoma. Ann Oncol J Eur Soc Med Oncol/ESMO. 2012, 23 (3): 736-742. 10.1093/annonc/mdr157.CrossRef
6.
Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010, 363 (19): 1812-1821. 10.1056/NEJMoa1002965.CrossRefPubMed
7.
Tamaru J, Hummel M, Mikata A, Stein H: [Hodgkin’s disease: the origin of HRS (Hodgkin and Reed-Sternberg) cells]. [Rinsho ketsueki] Japan J Clin Hematol. 1996, 37 (5): 426-429.
8.
Seitz V, Hummel M, Marafioti T, Anagnostopoulos I, Assaf C, Stein H: Detection of clonal T-cell receptor gamma-chain gene rearrangements in reed-Sternberg cells of classic Hodgkin disease. Blood. 2000, 95 (10): 3020-3024.PubMed
9.
Kuppers R: Identifying the precursors of Hodgkin and reed-Sternberg cells in Hodgkin’s disease: role of the germinal center in B-cell lymphomagenesis. J Acquir Immune Defic Syndr. 1999, 21 (Suppl 1): S74-S79.PubMed
10.
Steidl C, Connors JM, Gascoyne RD: Molecular pathogenesis of Hodgkin’s lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 2011, 29 (14): 1812-1826. 10.1200/JCO.2010.32.8401.CrossRefPubMed
11.
Schreck S, Friebel D, Buettner M, Distel L, Grabenbauer G, Young LS, Niedobitek G: Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol. 2009, 27 (1): 31-39. 10.1002/hon.878.CrossRefPubMed
12.
Skinnider BF, Mak TW: The role of cytokines in classical Hodgkin lymphoma. Blood. 2002, 99 (12): 4283-4297. 10.1182/blood-2002-01-0099.CrossRefPubMed
13.
Aldinucci D, Lorenzon D, Cattaruzza L, Pinto A, Gloghini A, Carbone A, Colombatti A: Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer J Int Du Cancer. 2008, 122 (4): 769-776. 10.1002/ijc.23119.CrossRef
14.
Niens M, Visser L, Nolte IM, van der Steege G, Diepstra A, Cordano P, Jarrett RF, Te Meerman GJ, Poppema S, van den Berg A: Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. Br J Haematol. 2008, 140 (5): 527-536. 10.1111/j.1365-2141.2007.06964.x.CrossRefPubMed
15.
Guermazi A, Brice P, de Kerviler EE, Ferme C, Hennequin C, Meignin V, Frija J: Extranodal Hodgkin disease: spectrum of disease. Radiographics Rev Public Radiol Soc N Am Inc. 2001, 21 (1): 161-179.
16.
Noordijk EM, Carde P, Dupouy N, Hagenbeek A, Krol AD, Kluin-Nelemans JC, Tirelli U, Monconduit M, Thomas J, Eghbali H: Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European organisation for research and treatment of cancer H7 randomized controlled trials. J Clin Oncol J Am Soc Clin Oncol. 2006, 24 (19): 3128-3135. 10.1200/JCO.2005.05.2746.CrossRef
17.
Wulfing P, Borchard J, Buerger H, Heidl S, Zanker KS, Kiesel L, Brandt B: HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Cli Cancer Res J Am Assoc Cancer Res. 2006, 12 (6): 1715-1720. 10.1158/1078-0432.CCR-05-2087.CrossRef
18.
Hoshimoto S, Shingai T, Morton DL, Kuo C, Faries MB, Chong K, Elashoff D, Wang HJ, Elashoff RM, Hoon DS: Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial. J Clin Oncol J Am Soc Clin Oncol. 2012, 30 (31): 3819-3826. 10.1200/JCO.2011.40.0887.CrossRef
19.
Wolf J, Kapp U, Bohlen H, Kornacker M, Schoch C, Stahl B, Mucke S, von Kalle C, Fonatsch C, Schaefer HE: Peripheral blood mononuclear cells of a patient with advanced Hodgkin’s lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells. Blood. 1996, 87 (8): 3418-3428.PubMed
20.
Diehl V, Kirchner HH, Schaadt M, Fonatsch C, Stein H, Gerdes J, Boie C: Hodgkin’s disease: establishment and characterization of four in vitro cell lies. J Cancer Res Clin Oncol. 1981, 101 (1): 111-124. 10.1007/BF00405072.CrossRefPubMed
21.
Mader A, Bruderlein S, Wegener S, Melzner I, Popov S, Muller-Hermelink HK, Barth TF, Viardot A, Moller P: U-HO1, a new cell line derived from a primary refractory classical Hodgkin lymphoma. Cytogenet Genome Res. 2007, 119 (3–4): 204-210.CrossRefPubMed
22.
Hsu SM, Zhao X, Chakraborty S, Liu YF, Whang-Peng J, Lok MS, Fukuhara S: Reed-Sternberg cells in Hodgkin’s cell lines HDLM, L-428, and KM-H2 are not actively replicating: lack of bromodeoxyuridine uptake by multinuclear cells in culture. Blood. 1988, 71 (5): 1382-1389.PubMed
23.
Karp PD, Paley S, Krieger CJ, Zhang P: An evidence ontology for use in pathway/genome databases. Pacif Sympo Biocomp. 2004, 190-201.
24.
Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD: Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med. 2010, 362 (10): 875-885. 10.1056/NEJMoa0905680.PubMedCentralCrossRefPubMed
25.
Josting A, Wolf J, Diehl V: Hodgkin disease: prognostic factors and treatment strategies. Curr Opin Oncol. 2000, 12 (5): 403-411. 10.1097/00001622-200009000-00004.CrossRefPubMed
26.
Khnykin D, Troen G, Berner JM, Delabie J: The expression of fibroblast growth factors and their receptors in Hodgkin’s lymphoma. J Pathol. 2006, 208 (3): 431-438. 10.1002/path.1900.CrossRefPubMed
27.
Murphy PR, Myal Y, Sato Y, Sato R, West M, Friesen HG: Elevated expression of basic fibroblast growth factor messenger ribonucleic acid in acoustic neuromas. Mol Endocrinol. 1989, 3 (2): 225-231. 10.1210/mend-3-2-225.CrossRefPubMed
28.
Tzankov A, Zimpfer A, Pehrs AC, Lugli A, Went P, Maurer R, Pileri S, Dirnhofer S: Expression of B-cell markers in classical hodgkin lymphoma: a tissue microarray analysis of 330 cases. Modern Pathol J US Can Acad Pathol Inc. 2003, 16 (11): 1141-1147.
29.
O’Connell FP, Pinkus JL, Pinkus GS: CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. Am J Clin Pathol. 2004, 121 (2): 254-263. 10.1309/617DWB5GNFWXHW4L.CrossRefPubMed
30.
Carbone A, Gloghini A, Gattei V, Degan M, Improta S, Aldinucci D, Canzonieri V, Perin T, Volpe R, Gaidano G: Reed-Sternberg cells of classical Hodgkin’s disease react with the plasma cell-specific monoclonal antibody B-B4 and express human syndecan-1. Blood. 1997, 89 (10): 3787-3794.PubMed
31.
Costes V, Magen V, Legouffe E, Durand L, Baldet P, Rossi JF, Klein B, Brochier J: The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens. Hum Pathol. 1999, 30 (12): 1405-1411. 10.1016/S0046-8177(99)90160-0.CrossRefPubMed
32.
Ruotsalainen T, Joensuu H, Mattson K, Salven P: High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer. Cancer Epidemiol Biomark Prev Pub Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2002, 11 (11): 1492-1495.
33.
Ueno K, Inoue Y, Kawaguchi T, Hosoe S, Kawahara M: Increased serum levels of basic fibroblast growth factor in lung cancer patients: relevance to response of therapy and prognosis. Lung Cancer. 2001, 31 (2–3): 213-219.CrossRefPubMed
34.
Salven P, Teerenhovi L, Joensuu H: A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin’s lymphoma. Blood. 1999, 94 (10): 3334-3339.PubMed
35.
Salven P, Orpana A, Teerenhovi L, Joensuu H: Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood. 2000, 96 (12): 3712-3718.PubMed
36.
Bertolini F, Paolucci M, Peccatori F, Cinieri S, Agazzi A, Ferrucci PF, Cocorocchio E, Goldhirsch A, Martinelli G: Angiogenic growth factors and endostatin in non-Hodgkin’s lymphoma. Br J Haematol. 1999, 106 (2): 504-509. 10.1046/j.1365-2141.1999.01547.x.CrossRefPubMed
37.
Pazgal I, Zimra Y, Tzabar C, Okon E, Rabizadeh E, Shaklai M, Bairey O: Expression of basic fibroblast growth factor is associated with poor outcome in non-Hodgkin’s lymphoma. Br J Cancer. 2002, 86 (11): 1770-1775. 10.1038/sj.bjc.6600330.PubMedCentralCrossRefPubMed
38.
Kowalska M, Janina K, Małgorzata F, Beata K, Alicja S, Joanna T, Jan W: Serum VEGF and bFGF levels in patients with Hodgkin’s lymphoma. NOWOTWORY J Oncol. 2007, 57 (4): 179e-182e.
39.
Salmivirta M, Heino J, Jalkanen M: Basic fibroblast growth factor-syndecan complex at cell surface or immobilized to matrix promotes cell growth. J Biol Chem. 1992, 267 (25): 17606-17610.PubMed
40.
Su G, Blaine SA, Qiao D, Friedl A: Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation. J Biol Chem. 2007, 282 (20): 14906-14915. 10.1074/jbc.M611739200.CrossRefPubMed
41.
Fitzgerald ML, Wang Z, Park PW, Murphy G, Bernfield M: Shedding of syndecan-1 and −4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol. 2000, 148 (4): 811-824. 10.1083/jcb.148.4.811.PubMedCentralCrossRefPubMed
42.
Zellweger T, Ninck C, Mirlacher M, Annefeld M, Glass AG, Gasser TC, Mihatsch MJ, Gelmann EP, Bubendorf L: Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate. 2003, 55 (1): 20-29. 10.1002/pros.10209.CrossRefPubMed
43.
Juuti A, Nordling S, Lundin J, Louhimo J, Haglund C: Syndecan-1 expression–a novel prognostic marker in pancreatic cancer. Oncology. 2005, 68 (2–3): 97-106.CrossRefPubMed
44.
Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, Angelo Mauri F, Veronese S, Caffo O, Lucenti A, Palma PD: High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer. 2003, 98 (3): 474-483. 10.1002/cncr.11515.CrossRefPubMed
45.
Vassilakopoulos TP, Kyrtsonis MC, Papadogiannis A, Nadali G, Angelopoulou MK, Tzenou T, Dimopoulou MN, Siakantaris MP, Kontopidou FN, Kalpadakis C: Serum levels of soluble syndecan-1 in Hodgkin’s lymphoma. Anticancer Res. 2005, 25 (6C): 4743-4746.PubMed
46.
Sebestyen A, Berczi L, Mihalik R, Paku S, Matolcsy A, Kopper L: Syndecan-1 (CD138) expression in human non-Hodgkin lymphomas. Br J Haematol. 1999, 104 (2): 412-419. 10.1046/j.1365-2141.1999.01211.x.CrossRefPubMed
47.
Kyrtsonis MC, Vassilakopoulos TP, Siakantaris MP, Kokoris SI, Gribabis DA, Dimopoulou MN, Angelopoulou MK, Pangalis GA: Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. Eur J Haematol. 2004, 72 (4): 252-258. 10.1046/j.0902-4441.2003.00205.x.CrossRefPubMed
48.
Leivonen M, Lundin J, Nordling S, von Boguslawski K, Haglund C: Prognostic value of syndecan-1 expression in breast cancer. Oncology. 2004, 67 (1): 11-18. 10.1159/000080280.CrossRefPubMed
49.
Molica S, Vitelli G, Mirabelli R, Digiesu G, Giannarelli D, Cuneo A, Ribatti D, Vacca A: Serum levels of syndecan-1 in B-cell chronic lymphocytic leukemia: correlation with the extent of angiogenesis and disease-progression risk in early disease. Leuk Lymphoma. 2006, 47 (6): 1034-1040. 10.1080/10428190500470358.CrossRefPubMed
50.
Aref S, Goda T, El-Sherbiny M: Syndecan-1 in multiple myeloma: relationship to conventional prognostic factors. Hematology. 2003, 8 (4): 221-228. 10.1080/1024533031000153630.CrossRefPubMed
51.
Joensuu H, Anttonen A, Eriksson M, Makitaro R, Alfthan H, Kinnula V, Leppa S: Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res. 2002, 62 (18): 5210-5217.PubMed
52.
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Joint ESCAAHAWHFTFfUDoMI, Authors/Task Force Members C, Thygesen K, Alpert JS et al.: Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012, 60 (16): 1581-1598. 10.1016/j.jacc.2012.08.001.CrossRefPubMed
53.
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Joint ESCAAHAWHFTFftUDoMI, Katus HA, Lindahl B, Morrow DA et al.: Third universal definition of myocardial infarction. Circulation. 2012, 126 (16): 2020-2035. 10.1161/CIR.0b013e31826e1058.CrossRefPubMed
54.
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD: Joint ESCAAHAWHFTFftUDoM: Third universal definition of myocardial infarction. Eur Heart J. 2012, 33 (20): 2551-2567. 10.1093/eurheartj/ehs184.CrossRefPubMed
55.
Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I: Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009, 69 (13): 5383-5391. 10.1158/0008-5472.CAN-08-3845.PubMedCentralCrossRefPubMed
56.
Porrata LF, Ristow K, Habermann TM, Ozsan N, Dogan A, Macon W, Colgan JP, Witzig TE, Inwards DJ, Ansell SM: Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma. Leuk Lymphoma. 2012, 53 (11): 2159-2165. 10.3109/10428194.2012.690605.CrossRefPubMed
57.
Koh YW, Kang HJ, Park C, Yoon DH, Kim S, Suh C, Kim JE, Kim CW, Huh J: Prognostic significance of the ratio of absolute neutrophil count to absolute lymphocyte count in classic Hodgkin lymphoma. Am J Clin Pathol. 2012, 138 (6): 846-854. 10.1309/AJCPO46GFKGNXCBR.CrossRefPubMed
58.
Koh YW, Kang HJ, Park C, Yoon DH, Kim S, Suh C, Go H, Kim JE, Kim CW, Huh J: The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin’s lymphoma: correlation with tumor-associated macrophages. Oncologist. 2012, 17 (6): 871-880. 10.1634/theoncologist.2012-0034.PubMedCentralCrossRefPubMed
59.
De Giorgi U, Mego M, Scarpi E, Giuliano M, Giordano A, Reuben JM, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M: Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clin Breast Cancer. 2012, 12 (4): 264-269. 10.1016/j.clbc.2012.04.004.CrossRefPubMed
60.
Watanabe K, Yamashita Y, Nakayama A, Hasegawa Y, Kojima H, Nagasawa T, Mori N: Varied B-cell immunophenotypes of Hodgkin/reed-Sternberg cells in classic Hodgkin’s disease. Histopathol. 2000, 36 (4): 353-361. 10.1046/j.1365-2559.2000.00830.x.CrossRef
61.
Carbone A, Gloghini A, Gaidano G, Franceschi S, Capello D, Drexler HG, Falini B, Dalla-Favera R: Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin’s disease. Blood. 1998, 92 (7): 2220-2228.PubMed
62.
Buettner M, Greiner A, Avramidou A, Jack HM, Niedobitek G: Evidence of abortive plasma cell differentiation in Hodgkin and reed-Sternberg cells of classical Hodgkin lymphoma. Hematol Oncol. 2005, 23 (3–4): 127-132.CrossRefPubMed
63.
Bai M, Panoulas V, Papoudou-Bai A, Horianopoulos N, Kitsoulis P, Stefanaki K, Rontogianni D, Agnantis NJ, Kanavaros P: B-cell differentiation immunophenotypes in classical Hodgkin lymphomas. Leuk Lymphoma. 2006, 47 (3): 495-501. 10.1080/10428190500306784.CrossRefPubMed
64.
Jones RJ, Gocke CD, Kasamon YL, Miller CB, Perkins B, Barber JP, Vala MS, Gerber JM, Gellert LL, Siedner M: Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood. 2009, 113 (23): 5920-5926. 10.1182/blood-2008-11-189688.PubMedCentralCrossRefPubMed
65.
Ibarrola De Andres C, Toscano R, Lahuerta JJ, Martinez-Gonzalez MA: Simultaneous occurrence of Hodgkin’s disease, nodal Langerhans’ cell histiocytosis and multiple myeloma IgA(kappa). Virchows Archiv Int J Pathol. 1999, 434 (3): 259-262. 10.1007/s004280050338.CrossRef
66.
Fujii H, Iwai T, Ueda Y, Nakagawa H: [Development of Hodgkin’s disease four years after autologous peripheral blood stem cell transplantation for multiple myeloma]. [Rinsho ketsueki] Japan J Clin Hematol. 2000, 41 (12): 1267-1272.
67.
Newcom SR, Gu L: Transforming growth factor beta 1 messenger RNA in reed-Sternberg cells in nodular sclerosing Hodgkin’s disease. J Clin Pathol. 1995, 48 (2): 160-163. 10.1136/jcp.48.2.160.PubMedCentralCrossRefPubMed
68.
Kuittinen O, Soini Y, Turpeenniemi-Hujanen T: Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin’s lymphoma. Eur J Haematol. 2002, 69 (4): 205-212. 10.1034/j.1600-0609.2002.02751.x.CrossRefPubMed
69.
Zucker-Franklin D, Grusky G, Baez L: Reed-Sternberg cells cultured from morphologically unidentifiable precursors in the blood of patients with Hodgkin’s disease. Hematol Oncol. 1983, 1 (2): 127-138.CrossRefPubMed
70.
Sitar G, Bianchi Santamaria A, Rosti V, Shaskin P, Blago R, Santamaria L, Ascari E: Giant cell formation in Hodgkin’s disease. Res Immunol. 1994, 145 (7): 499-515. 10.1016/S0923-2494(94)80069-3.CrossRefPubMed
Metadata
Title
Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients
Authors
Rajendra Gharbaran
Andre Goy
Takemi Tanaka
Jongwhan Park
Chris Kim
Nafis Hasan
Swathi Vemulapalli
Sreeja Sarojini
Madalina Tuluc
Kip Nalley
Pritish Bhattacharyya
Andrew Pecora
K Stephen Suh
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2013
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-6-62

Other articles of this Issue 1/2013

Journal of Hematology & Oncology 1/2013 Go to the issue

Review

MEK and the inhibitors: from bench to bedside

Research

IGF binding protein 2 is a cell-autonomous factor supporting survival and migration of acute leukemia cells

Research

TFPIα and TFPIβ are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity

Research

SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt

Research

Anti-CCR7 therapy exerts a potent anti-tumor activity in a xenograft model of human mantle cell lymphoma

Commentary

Lynch syndrome related endometrial cancer: clinical significance beyond the endometrium
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits